Published in World J Gastrointest Oncol on April 15, 2016
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer | NCT01373164
Immunotherapy Study for Surgically Resected Pancreatic Cancer | NCT01072981
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | NCT01959139
Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer | NCT01897415
Gene Therapy of Pancreatic Ductal Adenocarcinoma (TherGAP) | NCT01274455
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | NCT02117479
A Study of Ruxolitinib in Pancreatic Cancer Patients | NCT02119663
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
Pancreatic cancer. Lancet (2004) 11.63
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res (2014) 7.15
Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer (2004) 6.47
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell (2014) 5.87
Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg (1995) 5.66
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell (2014) 5.38
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
The pancreas cancer microenvironment. Clin Cancer Res (2012) 4.10
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 4.01
Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther (2007) 3.61
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol (2004) 3.56
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol (2011) 3.44
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Noncalcemic actions of vitamin D receptor ligands. Endocr Rev (2005) 3.34
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell (2012) 3.19
Dragging ras back in the ring. Cancer Cell (2014) 3.10
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol (2015) 2.98
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol (2007) 2.98
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (2013) 2.80
Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell (2011) 2.78
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell (2014) 2.74
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res (2008) 2.67
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas (2004) 2.48
Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 2.25
The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2007) 2.03
MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem (2010) 1.95
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun (2015) 1.94
An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem Biol (2011) 1.91
Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol (2008) 1.87
KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci (2014) 1.85
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer (2013) 1.85
Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest (2011) 1.80
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res (2011) 1.78
Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg (2007) 1.74
Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med (2003) 1.61
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res (2013) 1.60
Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett (2008) 1.53
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs (2011) 1.49
Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res (2014) 1.48
The epidermal growth factor receptor in human pancreatic cancer. J Pathol (1992) 1.47
Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig Dis Sci (2010) 1.45
Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res (2001) 1.44
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist (2011) 1.44
Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther (2013) 1.43
The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study. Am J Gastroenterol (2007) 1.43
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther (2009) 1.39
De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology (2000) 1.37
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol (2012) 1.34
Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer (2000) 1.30
Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol Immunol (2006) 1.26
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A (2011) 1.26
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer (2014) 1.17
Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett (2012) 1.16
EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res (2011) 1.16
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res (2011) 1.14
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer (2013) 1.11
Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett (2011) 1.10
Cancer: the matrix is now in control. Nat Med (2005) 1.09
The complex landscape of pancreatic cancer metabolism. Carcinogenesis (2014) 1.08
Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res (2001) 1.07
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg (2012) 1.06
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs (2012) 1.05